STIM NASDAQ
Neuronetics, Inc.
1W: +10.6%
1M: -14.4%
3M: +20.3%
YTD: +52.1%
1Y: -29.8%
3Y: +100.9%
5Y: -58.1%
$2.19
-0.05 (-2.23%)
Weekly Expected Move ±7.9%
$2
$2
$2
$2
$2
Credit Risk of going bust: higher than 90% of companies Debt: 34.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.15 (down 93%), Neuronetics, Inc. would be worth roughly what it owes.
Total debt $86.5M against a stock market value of $166.9M.
Distance to default 1.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.8M (short-term plus half of long-term), stock volatility 110.2%; Altman Z -3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.15 (down 93%), Neuronetics, Inc. would be worth roughly what it owes.
Total debt $86.5M against a stock market value of $166.9M.
Distance to default 1.53 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $30.8M (short-term plus half of long-term), stock volatility 110.2%; Altman Z -3.29. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (46)
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates
Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates
Neuronetics, Inc. (NASDAQ:STIM) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages
Neuronetics a new buy at B Riley on interventional psychiatry platform
NeuroStar Advances Practice Innovation with First-Ever TMS Integration with an EHR/EMR System
The best Quant-rated stocks trading below $10 right now
Neuronetics (STIM) Q2 2026 Earnings Call Transcript
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
Neuronetics Reports Second Quarter 2026 Financial and Operating Results
Shoulder Innovations, Inc. (SI) Reports Q2 Loss, Beats Revenue Estimates
Greenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, Maryland
Neuronetics, Inc. Q1 2026 Earnings Call Summary
Neuronetics (STIM) Q1 2026 Earnings Transcript
Neuronetics outlines $160M-$166M 2026 revenue outlook with focus on $2.5M-$3M annualized cost savings
Full Transcript: Neuronetics Q1 2026 Earnings Call
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics GAAP EPS of -$0.16, revenue of $34.5M
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Neuronetics Reports First Quarter 2026 Financial and Operating Results
Earnings Scheduled For May 5, 2026
Quant snapshot: Lumentum, Fastly among top-rated names as SUI Group, Service Properties lag
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
Optum/United Healthcare/United Behavioral Health Expands NeuroStar® TMS Coverage to Include Psychiatric Mental Health Nurse Practitioners
Deal Dispatch: Unilever Buys Grüns, Pershing Square Eyes Universal Music Group, Saks Global Reorganization Plan
12 Health Care Stocks Moving In Tuesday's Intraday Session
Neuronetics CFO Steven Pfanstiel to depart; company begins search for successor
Neuronetics Announces Chief Financial Officer Transition
Largest Independent Shareholder of Neuronetics, Inc., Jorey Chernett, Calls for Immediate and Comprehensive Review of Strategic Alternatives, Including Sale of TMS Business
Neuronetics (NASDAQ:STIM) Major Shareholder Jorey Chernett Acquires 169,472 Shares
Jorey Chernett Acquires 450,000 Shares of Neuronetics (NASDAQ:STIM) Stock
Jorey Chernett Purchases 607,400 Shares of Neuronetics (NASDAQ:STIM) Stock
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Up 22.2% in February
Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch
Neuronetics (STIM) Q4 2025 Earnings Transcript
Neuronetics GAAP EPS of -$0.10 beats by $0.01, revenue of $41.78M beats by $0.94M
Neuronetics appoints Dan Reuvers as chief executive officer
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Earnings Scheduled For March 17, 2026
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
Neuronetics (STIM) Stock Rises 41% After Hours: What's Going On?
Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
Neuronetics to Participate at the Piper Sandler 37th Annual Healthcare Conference